A modular phase I/II, open-label, multicenter study to evaluate the safety, tolerability and efficacy of AZD3470, a PRMT5 inhibitor, as Monotherapy and in combination with Anti-cancer Agents in participants with relapsed/refractory Hematologic Malignancies.

MyChart

Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
Request an Appointment

If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Appointment Information

New Patients Current Patients Referring Physicians
Donate Today